These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 11814515)

  • 41. Comparison of the Induction-to-Delivery Interval in Terminations of Pregnancy with or without Dilapan-S®.
    Vincienne M; Anselem O; Cordier AG; Le Ray C; Tsatsaris V; Benachi A; Goffinet F
    Fetal Diagn Ther; 2018; 43(1):61-67. PubMed ID: 28351055
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Misoprostol for labor induction in women with term premature rupture of membranes: a meta-analysis.
    Lin MG; Nuthalapaty FS; Carver AR; Case AS; Ramsey PS
    Obstet Gynecol; 2005 Sep; 106(3):593-601. PubMed ID: 16135593
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [New developments in labor induction].
    Yulzari-Roll V; Hod M; Bar J
    Harefuah; 2002 Apr; 141(4):369-73, 408. PubMed ID: 12017894
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Quality assessment of patient leaflets on misoprostol-induced labour: does written information adhere to international standards for patient involvement and informed consent?
    Clausen JA; Juhl M; Rydahl E
    BMJ Open; 2016 May; 6(5):e011333. PubMed ID: 27235300
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Misoprostol for cervical ripening and labor induction: a meta-analysis.
    Sanchez-Ramos L; Kaunitz AM; Wears RL; Delke I; Gaudier FL
    Obstet Gynecol; 1997 Apr; 89(4):633-42. PubMed ID: 9083326
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Assessment of efficacy and safety of medical treatment of non-viable first trimester pregnancy].
    Zwierzchowska A; Głuszak M; Jabiry-Zieniewicz Z; Banaszek-Wysoczańska A; Dziadecki W; Barcz E
    Ginekol Pol; 2012 Oct; 83(10):760-5. PubMed ID: 23383562
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Letrozole pretreatment prior to medical termination of pregnancy: a systematic review.
    Nash CM; Philp L; Shah P; Murphy KE
    Contraception; 2018 Jun; 97(6):504-509. PubMed ID: 29154779
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Flexible mifepristone and misoprostol administration interval for first-trimester medical termination.
    Wedisinghe L; Elsandabesee D
    Contraception; 2010 Apr; 81(4):269-74. PubMed ID: 20227541
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of vaginal pH on efficacy of misoprostol for cervical ripening and labor induction.
    Ramsey PS; Ogburn PL; Harris DY; Heise RH; Ramin KD
    Am J Obstet Gynecol; 2000 Jun; 182(6):1616-9. PubMed ID: 10871486
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Interpretation of national policy regarding community-based use of misoprostol for postpartum hemorrhage prevention in Ethiopia: a tale of two regions.
    Spangler SA; Gobezayehu AG; Hailemariam TG; Sibley LM
    J Midwifery Womens Health; 2014 Jan; 59 Suppl 1():S83-90. PubMed ID: 24588920
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Can women in less-developed countries use a simplified medical abortion regimen?
    Elul B; Hajri S; Ngoc NN; Ellertson C; Slama CB; Pearlman E; Winikoff B
    Lancet; 2001 May; 357(9266):1402-5. PubMed ID: 11356438
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Is it oral or vaginal; and should it be misoprostol or dinoprostone for cervical ripening? How to interpret a network meta-analysis.
    Hemming K; Price M
    BJOG; 2016 Feb; 123(3):355. PubMed ID: 26538480
    [No Abstract]   [Full Text] [Related]  

  • 53. Unsafe abortion requiring hospital admission in the Eastern Highlands of Papua New Guinea--a descriptive study of women's and health care workers' experiences.
    Vallely LM; Homiehombo P; Kelly-Hanku A; Whittaker A
    Reprod Health; 2015 Mar; 12():22. PubMed ID: 25889957
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Complications with use of misoprostol for abortion in Madagascar: between ease of access and lack of information.
    Pourette D; Mattern C; Ratovoson R; Raharimalala P
    Contraception; 2018 Feb; 97(2):116-121. PubMed ID: 29242087
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Perceptions of misoprostol among providers and women seeking post-abortion care in Zimbabwe.
    Maternowska MC; Mashu A; Moyo P; Withers M; Chipato T
    Reprod Health Matters; 2015 Feb; 22(44 Suppl 1):16-25. PubMed ID: 25702065
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Vaginal misoprostol for cervical ripening in term pregnancy.
    Weaver SP; Cook J; Nashelsky J
    Am Fam Physician; 2006 Feb; 73(3):511-2. PubMed ID: 16477899
    [No Abstract]   [Full Text] [Related]  

  • 57. Misoprostol use in obstetrics and gynecology in Brazil, Jamaica, and the United States.
    Clark S; Blum J; Blanchard K; Galvão L; Fletcher H; Winikoff B
    Int J Gynaecol Obstet; 2002 Jan; 76(1):65-74. PubMed ID: 11818096
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Current medical abortion care.
    Creinin MD
    Curr Womens Health Rep; 2003 Dec; 3(6):461-9. PubMed ID: 14613667
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Surgical versus medical methods for second trimester induced abortion.
    Lohr PA; Hayes JL; Gemzell-Danielsson K
    Cochrane Database Syst Rev; 2008 Jan; (1):CD006714. PubMed ID: 18254113
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Reaching women with instructions on misoprostol use in a Latin American country.
    Cohen J; Ortiz O; Llaguno SE; Goodyear L; Billings D; Martinez I
    Reprod Health Matters; 2005 Nov; 13(26):84-92. PubMed ID: 16291489
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.